Latest Breaking News On - Incannex board - Page 1 : comparemela.com

Incannex Announces Positive Topline Results from Phase 2

Highlights: PsiGAD1 trial achieves primary endpoint; PsiGAD psilocybin-assisted therapy demonstrated a statistically significant HAM-A reduction of 12.8.

South australiaUnited statesJoel lathamPaul liknaitzkyLaine yonkerEdison groupClinical psychedelic lab at monash universityIncannex healthcare incDrug administrationInvestigational new drugClinical psychedelic labMonash universityAbout generalised anxietyAnxiety disorderIncannex boardSecurities litigation reform act

Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

Highlights:PsiGAD1 trial achieves primary endpoint; PsiGAD psilocybin-assisted therapy demonstrated a statistically significant HAM-A reduction of.

South australiaUnited statesLaine yonkerJoel lathamPaul liknaitzkyIncannex healthcare incEdison groupDrug administrationClinical psychedelic lab at monash universityInvestigational new drugClinical psychedelic labMonash universityAbout generalised anxietyAnxiety disorderIncannex boardSecurities litigation reform act

Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-N for tobacco smoking cessation and control of relapse. The pre-IND teleconference included representatives f

United statesLaine yonkerJoel lathamDrug administrationEdison groupIncannex healthcare incInvestigational new drugIncannex boardSecurities litigation reform actExecutive officerRelations contactNicotine replacement therapyNicotine addictionIncannex healthcare incFood and drug administrationInvestigational new drug

Clarion Clinics Receives Ethics Board Endorsement For The First Dedicated Psychedelic-Assisted Therapy Clinic In Australia

Clarion Clinics Receives Ethics Board Endorsement For The First Dedicated Psychedelic-Assisted Therapy Clinic In Australia
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesJoel lathamPeter widdowsIncannex healthcare ltd nasdaqEdison groupIncannex healthcare incTherapeutic goods administrationHuman research ethics committeeClarion clinicsHealthcare ltdAuthorised prescriber schemeTreatment resistant depressionPost traumatic stress disorderAuthorised prescriberMelbourne clarion clinicYarra riverfront

Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

MELBOURNE, Australia and NEW YORK, Dec. 06, 2023 Incannex Healthcare Inc. , , a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine.

United statesJoel lathamNational healthNutrition examinationHealth foundationEdison groupIncannex healthcare incGlobenewswire incAmerican thoracic societyInvestigational new drugIncannex boardSecurities litigation reform actChief executiveRelations contactMed revDisordered breathing